Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping.

IF 3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2025-04-01 DOI:10.1007/s00277-025-06231-2

Emile Niyonizeye, Xiaoqian Wang, Dongyao Yan, Seidu A Richard, Huijun Ren, Liyan Fu, Yaoyao Chen, Xiaogeng Yuan, Baohong Yue

{"title":"Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping.","authors":"Emile Niyonizeye, Xiaoqian Wang, Dongyao Yan, Seidu A Richard, Huijun Ren, Liyan Fu, Yaoyao Chen, Xiaogeng Yuan, Baohong Yue","doi":"10.1007/s00277-025-06231-2","DOIUrl":null,"url":null,"abstract":"<p><p>The diagnosis and differential diagnosis of typical lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma(SLL) especially atypical CLL/SLL (aCLL/SLL), and mantle cell lymphoma (MCL) remains highly challenging. Thus, we evaluated the accuracy of the combination of the Moreau score system (MSS) indicators (markers), with three new indicators CD19/CD20 ratio, CD200, and CD43 in diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL. We retrospectively retrieved data from peripheral blood, bone marrow, and lymph nodes of 120 patients comprising 64 typical CLL, 10 atypical CLL, and 46 MCL from March 2020 to September 2023 at the First Affiliated Hospital of Zhengzhou University. Multiparametric evaluation flow cytometry and immunophenotype were obtained via a B-cell panel and pathological reports were carried out. We observe that the new score system (NSS) and the MSS had the same specificity. However, the NSS demonstrated to have superior sensitivity compared to MSS. Adding three new markers CD19/CD20, CD200, and CD43 is accountable for the superior sensitivity in our NSS. Also, a combination of markers such as CD19, CD20, CD5, CD23, CD79b, FMC7, SmIg, CD22, CD43, CD200, the ratio CD19/CD20 may be a potential differentiating modality for typical CLL/SLL, atypical CLL/SLL, and MCL. Adding the CD19/CD20 ratio, CD43, and CD200 indicators to the MSS indicators could be potentially accurate diagnostic and differential diagnosis modality for typical CLL/SLL, atypical CLL/SLL, and MCL.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06231-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The diagnosis and differential diagnosis of typical lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma(SLL) especially atypical CLL/SLL (aCLL/SLL), and mantle cell lymphoma (MCL) remains highly challenging. Thus, we evaluated the accuracy of the combination of the Moreau score system (MSS) indicators (markers), with three new indicators CD19/CD20 ratio, CD200, and CD43 in diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL. We retrospectively retrieved data from peripheral blood, bone marrow, and lymph nodes of 120 patients comprising 64 typical CLL, 10 atypical CLL, and 46 MCL from March 2020 to September 2023 at the First Affiliated Hospital of Zhengzhou University. Multiparametric evaluation flow cytometry and immunophenotype were obtained via a B-cell panel and pathological reports were carried out. We observe that the new score system (NSS) and the MSS had the same specificity. However, the NSS demonstrated to have superior sensitivity compared to MSS. Adding three new markers CD19/CD20, CD200, and CD43 is accountable for the superior sensitivity in our NSS. Also, a combination of markers such as CD19, CD20, CD5, CD23, CD79b, FMC7, SmIg, CD22, CD43, CD200, the ratio CD19/CD20 may be a potential differentiating modality for typical CLL/SLL, atypical CLL/SLL, and MCL. Adding the CD19/CD20 ratio, CD43, and CD200 indicators to the MSS indicators could be potentially accurate diagnostic and differential diagnosis modality for typical CLL/SLL, atypical CLL/SLL, and MCL.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.